TNBI Tanke Biosciences Corp
Grain Mill Products · OTC · SEC CIK 1452011 · Fiscal year ends 12/31
Financial factors as of 2013-09-30 (2013Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-19.5%
TTM net income YoY-164.1%
TTM EPS YoY-165.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin32.3%
Operating margin-0.2%
Net margin-7.1%
FCF margin-27.3%
EBITDA margin2.1%
Returns
ROE-10.2%
ROA-5.7%
ROIC (approx.)-0.4%
Asset turnover0.80x
Leverage & solvency
Liabilities / assets45.5%
Debt / equity0.12x
Current ratio1.61x
Interest coverage-0.10x
Cash quality & payout
Operating cash flow / net income2.30x
Accruals ratio7.4%
Payout ratio—
Capex / revenue10.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20122012-12-31 | FY20112011-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $28.56M | $23.83M |
| Cost of revenue | $18.62M | $15.06M |
| Gross profit | $9.94M | $8.77M |
| R&D expense | $290,691 | $246,038 |
| SG&A expense | $2.57M | $4.49M |
| Operating income | $4.53M | $1.74M |
| Interest expense | $1.45M | $1.36M |
| Pretax income | $602,591 | -$2.45M |
| Income tax | $831,597 | $681,321 |
| Net income | -$210,247 | -$3.14M |
| EBITDA | $5.17M | $2.14M |
| EPS (basic) | -0.02 | -0.24 |
| EPS (diluted) | -0.02 | -0.24 |
| Weighted avg. shares (diluted) | 13.32M | 13.08M |
| Balance sheet | ||
| Cash & equivalents | $6.17M | $7.70M |
| Receivables | $1.99M | $1.92M |
| Inventory | $1.41M | $1.19M |
| Current assets | $22.37M | $18.91M |
| PP&E, net | $4.81M | $4.77M |
| Intangibles | $1.24M | $838,089 |
| Total assets | $28.85M | $24.89M |
| Current liabilities | $12.10M | $3.55M |
| Short-term debt | $1.27M | $785,456 |
| Long-term debt | $792,567 | $628,365 |
| Total debt | $2.06M | $1.41M |
| Total liabilities | $12.93M | $9.03M |
| Shareholders' equity | $15.75M | $15.85M |
| Net debt | -$4.11M | -$6.29M |
| Shares outstanding | 13.32M | 13.32M |
| Cash flow statement | ||
| Operating cash flow | -$1.18M | $3.65M |
| Capital expenditure | $856,361 | $701,022 |
| Free cash flow | -$2.04M | $2.95M |
| Investing cash flow | -$1.53M | -$3.67M |
| Financing cash flow | $1.12M | $5.82M |
| Depreciation & amortization | $636,286 | $400,013 |
| Stock-based compensation | — | $2.49M |
Free plan shows the latest 2 periods; Pro shows all 4 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.